Obesity Clinical Trial
Official title:
A Multiple Health Behavior Change Intervention for Overweight and Obese Smokers
Verified date | February 2023 |
Source | Brown University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the efficacy, acceptability, and feasibility of an intervention that provides a behavioral weight gain prevention intervention in advance of smoking cessation treatment in individuals with overweight or obesity who smoke cigarettes. The primary aim of this study is to determine feasibility and acceptability and initial efficacy regarding whether preceding 8 weeks of smoking cessation treatment with 8 weeks of self-regulation strategies + large changes for weight gain prevention (SR), compared to 8 weeks of healthy lifestyle education (LE), will result in greater smoking cessation and reduced weight gain. Secondary aims are to study effects on self-efficacy for managing weight and for quitting smoking, negative affect, and delayed reward discounting. Methods: Individuals with overweight or obesity who smoke cigarettes will participate in a 16-week group-based multiple health behavior change intervention. Groups will be randomly assigned to receive either 8 weeks of SR followed by 8 weeks of smoking cessation treatment or 8 weeks of LE followed by 8 weeks of smoking cessation treatment. Smoking cessation treatment in both conditions will include counseling and combination nicotine replacement therapy (patch + lozenges), with a quit day at week 9 of the 16-week intervention. Assessments will occur at baseline, on quit day and 1, 2, and 3 months later. Determining the viability of this strategy in terms of effects on both smoking and weight has high significance to public health.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | January 2025 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - BMI = 25 kg/m2 - smoked = 5 cigarettes/day during the past year - self-reported motivation to quit smoking - self-reported desire to prevent or minimize weight gain during smoking cessation - ability to understand informed consent - access to a smartphone or tablet Exclusion Criteria: - current smoking cessation or weight loss treatment/medication - more than 1 day/week use of tobacco or nicotine from sources other than cigarettes (other than non-daily use of e-cigarettes in addition to combustible cigarettes) - weight loss of 20 lbs or more within the past 6 months - self-reported diagnosis or treatment for an alcohol or substance use disorder within the past 6 months (with the exception of maintenance therapies) - endorsing recent symptomology suggestive of an eating disorder, an alcohol or substance use disorder, severe depression, or suicidal ideation - self-reported diagnosis or treatment or evidence of an eating disorder or severe psychiatric disorder (e.g., schizophrenia or bipolar disorder) - not stabilized on psychotropic medications - current use of medications known to interact with smoking cessation - clinically significant medical condition |
Country | Name | City | State |
---|---|---|---|
United States | Brown University School of Public Health | Providence | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Brown University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Self-efficacy for quitting smoking | The Smoking Self-Efficacy Questionnaire will be used to compare baseline to quit day. Scores range from 12 to 60; higher scores indicate a better outcome. | week 9 (quit day) | |
Other | Self-efficacy for weight management after quitting smoking | The Weight-Efficacy After Quitting scale will be used to compare baseline to quit day. Scores range from 6 to 60; higher scores indicate a better outcome. | week 9 (quit day) | |
Other | Delay discounting | The Monetary Choice Questionnaire will be used to compare baseline to quit day. Responses will be used to calculate discount rate (k), and the proportion of immediate reward choices; higher values indicate more impulsivity. | week 9 (quit day) | |
Other | Negative affect | Negative affect will be assessed using a measure called the Positive and Negative Affective Schedule. It will be used to compare baseline to quit day; higher values indicate higher negative affect. | week 9 (quit day) | |
Other | Treatment satisfaction | Treatment satisfaction during the first half of treatment will be assessed via questionnaire, with higher scores indicating greater satisfaction. | week 9 (quit day) | |
Other | Study retention | The percentage of participants completing the final outcome assessment will be used to determine study retention. | 3 months post-quit (end of study) | |
Primary | 7-day point-prevalence abstinence from smoking | biochemically-verified 7-day-point prevalence abstinence from smoking | 2 months post-quit (end of treatment) | |
Primary | Weight Change | body weight (lbs) | change from baseline to week 9 (quit day) to 1, 2, 3 months post-quit | |
Primary | Treatment attendance | The percentage of treatment sessions attended through week 10 (one week post-quit) will be used as a measure of attendance to demonstrate feasibility and acceptability | Treatment weeks 1-10 | |
Secondary | 7-day point-prevalence abstinence from smoking | biochemically-verified 7-day-point prevalence abstinence from smoking | week 9 (quit day), 1, 2, 3 months post-quit | |
Secondary | Number of cigarettes smoked/day | Timeline Follow Back (TLFB) interview will assess self-reported number of cigarettes smoked each day, summed over past 28 days | week 9 (quit day), 1, 2, 3 months post-quit | |
Secondary | Achievement of =50% reduction in cigarettes per day smoked | Relative to baseline, whether number of cigarettes smoked in the past 28 days has decreased by =50% | week 9 (quit day), 1, 2, 3 months post-quit | |
Secondary | Duration of longest period of abstinence from smoking | Timeline Follow Back (TLFB) interview will assess self-reported smoking abstinence each day. The longest number of contiguous abstinence days will be recorded starting at quit day. | 1, 2, 3 months post-quit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |